CDX
COLO 205
Tumor indication
Bowel
Tumor subtype
Duke's type D, Colorectal Adenocarcinoma
Description
COLO 205 (Colorectal Cancer CDX Model)
The COLO 205 colorectal cancer cell line was derived from ascites of a patient with metastatic adenocarcinoma. It is KRAS and BRAF wild-type, offering a distinct profile compared to other colorectal cancer models. COLO 205 has been extensively used in preclinical drug testing. Its genetic stability makes it a reproducible tool in colon cancer studies.
Key Features:
- Derived from metastatic colorectal adenocarcinoma.
- KRAS/BRAF wild-type.
- Epithelial morphology with glandular growth.
- Consistent tumor formation in xenografts.
Applications:
COLO 205 is applied in screening therapies for colorectal cancer, especially those targeting KRAS-independent pathways. It supports biomarker validation and mechanistic studies of colon tumor biology. Researchers frequently use it as a comparator to KRAS- or BRAF-mutant lines. Its stable genetics make it suitable for translational research.
Details
- Tumor indication
- Bowel
- Tumor subtype
- Duke's type D, Colorectal Adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.